Global Market Report for Electronic Nicotine Delivery Systems (ENDS)

Aug.16.2022
Global Market Report for Electronic Nicotine Delivery Systems (ENDS)
The global market for electronic nicotine delivery systems, including e-cigarettes, is predicted to grow rapidly through 2026.

The Business Research Company has released a market research report that predicts the size and trends of the global market for electronic nicotine delivery systems, including e-cigarettes, from 2022 to 2026.


According to a global market report by a business research company, the vaporizer, electronic cigarette, and other electronic nicotine delivery systems (ENDS) market is expected to grow from $19.92 billion in 2021 to $25.03 billion in 2022, with a compound annual growth rate (CAGR) of 25.6%. The market growth is mainly due to companies resuming operations and adapting to a new normal, while recovering from the impact of COVID-19, which earlier resulted in restrictive measures including social distancing, remote work, and the closure of commercial activities, posing operational challenges. The vaporizer, electronic cigarette, and other ENDS market is expected to reach $55.99 billion in 2026, with a CAGR of 22.3%. The awareness of health issues caused by traditional cigarettes among smokers is driving the growth of the electronic cigarette market.


The main trends in the market for vaporizers, electronic cigarettes, and other electronic nicotine delivery systems (ENDS) are as follows: There is an increasing demand for medicinal cannabis vaporizers in the vaporizer market. Cannabis vaporizers have controlled heating technology and can precisely adjust heating temperature through the display screen on the device, allowing users to fully control the density of the aerosol produced. The TBRC's 2022 Global Market Report on Vaporizers, Electronic Cigarettes, and Other Electronic Nicotine Delivery Systems (ENDS) includes the following information:


This report categorizes the market based on geographical regions including the Asia Pacific, China, Western Europe, Eastern Europe, North America, the United States, South America, the Middle East, and Africa. It also reflects segmentation by country, including Australia, Brazil, mainland China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the United Kingdom, and the United States, as well as by product type, including atomizers, e-cigarettes, and other electronic nicotine delivery systems. Within these product categories, e-cigarettes can be further divided into disposable, rechargeable, and modular types, while atomizers include e-cigarette atomizers, cannabis atomizers, and medical atomizers. The global market for e-cigarettes and other ENDS can be segmented geographically into North America, South America, the Asia Pacific, Eastern Europe, Western Europe, the Middle East, and Africa. The APAC region holds the largest market share. Leading market players mentioned in the report include Dash Vapes, Hubbly Bubbly, Liquideu, Nice Vapor, Pacific Smoke International, Puff Ecig, Simple Vape Co. London Ltd, Smokio, Vape Escapes, and Vapor Line. The report also highlights current trends, opportunities, strategies, and more. Disclaimer:


This article is compiled from third-party information and is intended only for industry exchange and learning.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the truthfulness or accuracy of the content. The compilation of this article is only intended for industry exchanges and research purposes.


Due to the limitations of the translation skills, the translated article may not fully express the original meaning. Please refer to the original text for accuracy.


In terms of any domestic, Hong Kong, Macau, Taiwan, or foreign-related expressions and positions, 2FIRSTS is fully aligned with the Chinese government.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei Industrial Co., Ltd. disclosed several oral nicotine-related patent applications in August 2026, including two that approach staged nicotine release from different directions. One uses a high-viscosity membrane that forms inside the pouch after contact with saliva to slow rapid early release, while the other uses gradient particles with a faster-disintegrating outer layer and a slower core to create a fast-to-sustained release profile. Together, the filings explore how nicotine pouches could balance initial delivery with release later in use.
Sep.03
Philippines Weighs Unified Vape Tax as Lawmakers Back Risk-Based Rates and Government Seeks to Fill ₱66 Billion Revenue Gap
Philippines Weighs Unified Vape Tax as Lawmakers Back Risk-Based Rates and Government Seeks to Fill ₱66 Billion Revenue Gap
Philippine lawmakers are considering an overhaul of the country's vape excise-tax regime to eliminate the wide gap between taxes on nicotine salt and freebase nicotine liquids and reduce incentives for misdeclaration. House Bill 5364, filed by Rep. Rufus Rodriguez and Rep. Maximo Rodriguez Jr., would impose a unified ₱10-per-milliliter tax on vapor products, with 5% annual increases beginning in 2027. Rodriguez says the proposal could generate an average ₱6 billion in annual collections from 2027 through 2030. The debate comes as the Philippine government considers tobacco, vape and other health-tax reforms to help offset around ₱66 billion in revenue expected to be forgone under a proposed tax-relief package.
Aug.18
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
Special Report|AIR H1 Revenue Rises 3.7% as Shisha Volumes Fall 9%, Testing Its Shift Beyond Traditional Hookah
AIR’s first half-year results as a listed company offer a new test of how far a traditional hookah business can transform. H1 2026 revenue rose 3.7%, even as Flavored Shisha Molasses shipments fell 9%, with pricing and mix supporting growth. Traditional shisha still generates almost all revenue, while OOKA, Crown Switch, Greentank and U.S. regulatory spending point to accelerating diversification. The next test is whether those investments can become a second business of meaningful scale and profitability.
Capital Markets
Aug.21
Russia Adds Vapes to “Strategic Goods” List, Illegal Cross-Border Trade Faces Up to Five Years in Prison
Russia Adds Vapes to “Strategic Goods” List, Illegal Cross-Border Trade Faces Up to Five Years in Prison
Russia will place e-cigarettes and related nicotine products under its “strategic goods” framework from August 20, 2026. According to TVP World’s report published on August 19, the newly listed items include e-cigarettes, electronic smoking devices, vape liquids and nicotine salts. Individuals who illegally move these products across Russia’s customs border or its state border with other Eurasian Economic Union (EAEU) members could face up to five years in prison if shipment values exceed 100,000 rubles (about €1,000), provided all elements of a criminal offence are established.
Aug.20
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Philip Morris Japan (PMJ) launched the IQOS ILUMA i PRIME Ginza Limited Model Set in Tokyo on September 4, 2026, alongside the opening of IQOS Flagship Ginza, the brand’s first global flagship store. The Oasis Blue edition is limited to 1,814 individually numbered units, with the figure derived from the store’s address at Ginza 1-8-14. The set also includes two Yamanaka-nuri glasses and special packaging, priced at JPY 11,980 and sold exclusively at the Ginza flagship.
Sep.07